Core Viewpoint - The initial public offering (IPO) of Huazhang Biotech-B (02396) on December 22 saw a significant drop in share price, closing at 27.00 HKD, a decline of 29.32% from the issue price of 38.20 HKD, which was below investor expectations [1][14]. Group 1: IPO Performance - On the first trading day, Huazhang Biotech's stock price fell as much as 21.68%, reaching a low of 31 HKD before closing at 27.00 HKD [1]. - The company was initially viewed as a promising investment due to its status as the "first PDGF stock in Hong Kong," but the performance on the first day was disappointing for many investors [1][14]. - The stock experienced a significant oversubscription of 791.95 times during the global offering, indicating strong initial interest [3]. Group 2: Financial Details - The global offering consisted of 17.6488 million H-shares, with 90% allocated for international sale and 10% for public sale, raising approximately 674 million HKD [3]. - The company set the issue price at the lower end of the range, with a total fundraising target of approximately 787 million HKD [4]. - The entry fee for investors was notably high at 10,302.88 HKD, which is above the average for Hong Kong IPOs this year [6]. Group 3: Market Context - The company operates in the biotechnology sector, focusing on developing and commercializing protein-based therapies, particularly in wound healing [11]. - Huazhang Biotech's core products, Pro-101-1 and Pro-101-2, are currently in clinical trials for treating burn injuries and diabetic foot ulcers, respectively [13]. - The Chinese diabetes market is projected to grow from 4.7 billion USD in 2023 to 9.3 billion USD by 2032, with a compound annual growth rate (CAGR) of 7.9% [12]. Group 4: Challenges and Risks - Despite the promising market potential, the company is classified as an "unprofitable 18A" entity, indicating high research and development costs without current product sales [14]. - The company reported minimal revenues of 472,000 HKD and 261,000 HKD for 2023 and 2024, respectively, with significant net losses attributed to R&D and administrative expenses [14]. - The absence of cornerstone investors and reliance on institutional investors for price stabilization may have contributed to the stock's poor performance on its debut [8][9].